-
1 Comment
Shenzhen Weiguang Biological Products Co., Ltd is currently in a long term downtrend where the price is trading 19.8% below its 200 day moving average.
From a valuation standpoint, the stock is 8.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 10.4.
Shenzhen Weiguang Biological Products Co., Ltd's total revenue rose by 15.3% to $200M since the same quarter in the previous year.
Its net income has increased by 11.8% to $43M since the same quarter in the previous year.
Finally, its free cash flow fell by 188.9% to $-47M since the same quarter in the previous year.
Based on the above factors, Shenzhen Weiguang Biological Products Co., Ltd gets an overall score of 2/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100002Q58 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 33 |
|---|---|
| Beta | 0.24 |
| Market Cap | 7B |
| PE Ratio | 26.62 |
| Dividend Yield | 1.4% |
Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human albumin, intravenous human immunoglobulin (pH4), rabies immunoglobulin, human fibrinogen, coagulation factor, trace proteins, as well as a total of 9 varieties and 21 specifications. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985 and is based in Shenzhen, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002880.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
